Latest Innovation News

Ventia Services Group has secured a substantial $935 million contract to provide clothing services to the Australian Defence Force, marking a significant expansion of its defence sector presence.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Hiremii Group has successfully raised $650,000 through an oversubscribed placement, underscoring strong investor confidence as it pushes forward with commercialising its AI-driven recruitment platform.

DigitalX Limited reveals a robust A$101 million treasury portfolio dominated by Bitcoin holdings and a significant cash increase from Solana sales, underpinning its ambitious target of accumulating 2,100 Bitcoins by 2027.

Western Mines Group has been awarded a $180,000 government grant to fund further drilling at its Mulga Tank nickel project, targeting a promising komatiite mineral system. This funding supports the company’s ongoing exploration efforts to delineate a significant nickel sulphide deposit in Western Australia.

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

Li-S Energy has partnered with Praetorian Aeronautics to integrate advanced lithium-sulfur batteries into autonomous interceptor drones, aiming to boost Australia's sovereign defence capabilities.

1414 Degrees has acquired exclusive global rights to a patented silicon nanoparticle technology from George Washington University, aiming to revolutionize lithium-ion battery anodes with higher capacity and faster charging. The company also raised $1.214 million to accelerate commercialisation and OEM engagement starting late 2025.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Immutep Limited has enrolled over 170 patients in its global Phase III TACTI-004 trial for advanced non-small cell lung cancer, surpassing the threshold needed for a futility analysis expected in early 2026.

Guzman y Gomez reports robust Q1 FY26 sales growth and network expansion, alongside a significant $100 million share buyback to enhance shareholder value.